# Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease

> **NCT00598962** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center at Tyler** · enrollment: 58 (actual)

## Conditions studied

- Mycobacterium Avium Complex

## Interventions

- **DRUG:** Azithromycin
- **DRUG:** Rifabutin/rifampin

## Key facts

- **NCT ID:** NCT00598962
- **Lead sponsor:** The University of Texas Health Science Center at Tyler
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-12
- **Primary completion:** 2006-11
- **Final completion:** 2017-05-18
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00598962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00598962, "Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00598962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*